NCT05388773View on ClinicalTrials.gov

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Oropharynx Cancer
Interventions
PROCEDURE

therapeutic conventional surgery

Transoral surgical resection of tumor(s).

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

quality-of-life assessment

Ancillary studies.

RADIATION

intensity-modulated radiation therapy

Low-dose IMRT

DRUG

Cisplatin

Given IV.

DRUG

Carboplatin

Given IV

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

Sponsors

Lead Sponsor

Heath Skinner
All Listed Sponsors
lead

Heath Skinner

OTHER

NCT05388773 - Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | Biotech Hunter | Biotech Hunter